BellRing Brands ROI - Return on Investment 2019-2024 | BRBR

BellRing Brands return on investment for the quarter ending June 30, 2024 was 39.24.

  • BellRing Brands average return on investment for 2023 was 27.95, a 490.91% increase from 2022.
  • BellRing Brands average return on investment for 2022 was -7.15, a 441.67% decline from 2021.
  • BellRing Brands average return on investment for 2021 was -1.32, a 58.62% increase from 2020.

Roi - return on investment can be defined as an indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity.

BellRing Brands ROI - Return on Investment 2019-2024 | BRBR

  • BellRing Brands average return on investment for 2023 was 27.95, a 490.91% increase from 2022.
  • BellRing Brands average return on investment for 2022 was -7.15, a 441.67% decline from 2021.
  • BellRing Brands average return on investment for 2021 was -1.32, a 58.62% increase from 2020.

Roi - return on investment can be defined as an indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$205.5B
Stryker (SYK)$138.7B
Boston Scientific (BSX)$121.5B
Medtronic (MDT)$113.7B
EssilorLuxottica (ESLOY)$104.2B
Haleon (HLN)$48.6B
Lonza Group Ag (LZAGY)$45.9B
ResMed (RMD)$36.9B
Koninklijke Philips (PHG)$29.3B
Terumo (TRUMY)$27.8B
Zimmer Biomet Holdings (ZBH)$21.6B
Baxter (BAX)$20.3B
Insulet (PODD)$16.5B
Smith & Nephew SNATS (SNN)$13.5B
Bio-Rad Laboratories (BIO)$9.3B
Demant (WILYY)$9.2B
Lantheus Holdings (LNTH)$7.3B
ICU Medical (ICUI)$4.3B
Haemonetics (HAE)$3.9B
TG Therapeutics (TGTX)$3.9B
GN Store Nord (GNNDY)$3.8B
Perrigo (PRGO)$3.8B
Neogen (NEOG)$3.7B
Prestige Consumer Healthcare (PBH)$3.6B
Envista Holdings (NVST)$3.3B
QuidelOrtho (QDEL)$3.1B
Agios Pharmaceuticals (AGIO)$2.6B
Maravai LifeSciences Holdings (MRVI)$2.3B
Green Thumb Industries (GTBIF)$2.2B
LeMaitre Vascular (LMAT)$2B